

## **Rapid-VIDITEST**

### **COVID-19 + Influenza A+B Antigen**

***Rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2 Influenza A and Influenza B virus antigens present in human nasopharynx.***

#### **Instruction manual**

Producer: VIDIA spol. s r.o., Nad Safinou II 365, 252 50 Vestec, Czech Republic,  
Tel.: +420 261 090 565, e-mail: [orders@vidia.cz](mailto:orders@vidia.cz), web: [www.vidia.cz](http://www.vidia.cz)

*For professional in vitro diagnostic use only.*

#### **INTENDED USE:**

Rapid-VIDITEST COVID-19 + Influenza A+B Antigen is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2, Influenza A and Influenza B virus antigens in nasopharyngeal swab specimens from individuals with suspected SARS-CoV-2 / Influenza infection in conjunction with clinical presentation and the results of other laboratory tests.

Results are for the detection of SARS-CoV-2 and Influenza A+B Antigens. An antigen is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.

Negative results do not preclude SARS-CoV-2 / Influenza A+B infection and should not be used as the sole basis for treatment or patient management decisions. Negative results should be treated as presumptive and confirmed with a molecular assay, if necessary for patient management. Negative results should be considered in the context of a patient's recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19 / Influenza A+B.

The Rapid-VIDITEST COVID-19 + Influenza A+B Antigen is intended for use by trained clinical laboratory personnel.

#### **INTRODUCTION:**

The novel coronaviruses belong to the  $\beta$  genus. COVID-19 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.

Influenza (commonly known as 'flu') is a highly contagious, acute viral infection of the respiratory tract. It is a communicable disease easily transmitted through the coughing and sneezing of aerosolized droplets containing live virus. Influenza outbreaks occur each year during the fall and winter months. Type A viruses are typically more prevalent than type B viruses and are associated with most serious influenza epidemics, while type B infections are usually milder.

The gold standard of laboratory diagnosis is 14-day cell culture with one of a variety of cell lines that can support the growth of influenza virus. Cell culture has limited clinical utility, as results are obtained too late in the clinical course for effective patient intervention. Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a newer method that is generally more sensitive than culture with improved detection rates over culture of 2-23%. However, RT-PCR is expensive, complex and must be performed in specialized laboratories.

### **PRINCIPLE OF THE TEST:**

The Rapid-VIDITEST COVID-19 Antigen is a qualitative membrane-based immunoassay for the detection of SARS-CoV-2 Antigens in human nasopharyngeal swab specimen. SARS-CoV-2 antibody is coated in the test line region. During testing, the specimen reacts with SARS-CoV-2 antibody-coated particles in the test. The mixture then migrates upward on the membrane by capillary action and reacts with the SARS-CoV-2 antibody in test line region. If the specimen contains SARS-CoV-2 Antigens, a colored line will appear in test line region as a result of this. If the specimen does not contain antigens to SARS-CoV-2, no colored line will appear in the test line region, indicating a negative result. To serve as a procedural control, a colored line will always appear in the control line region, indicating that the proper volume of specimen has been added and membrane wicking has occurred.

The Rapid-VIDITEST Influenza A+B is a qualitative, lateral flow immunoassay for the detection of Influenza A and Influenza B antigen in human nasopharyngeal swab specimen. In this test, antibody specific to the Influenza A and Influenza B is separately coated on the test line regions of the test. During testing, the extracted specimen reacts with the antibody to Influenza A and / or Influenza B that are coated onto particles. The mixture migrates up the membrane to react with the antibody to Influenza A and / or Influenza B on the membrane and generate one or two colored lines in the test regions. The presence of this colored line in either or both of the test regions indicates a positive result. To serve as a procedural control, a colored line will always appear in the control region if the test has performed properly.

### **REAGENTS:**

The test contains anti-SARS-CoV-2, anti-Influenza A and anti-Influenza B as the capture reagent, anti-SARS-CoV-2 , anti-Influenza A and anti-Influenza B as the detection reagent.

### **PRECAUTIONS:**

1. This package insert must be read completely before performing the test. Failure to follow directions in package insert may yield inaccurate test results.
2. For professional *in vitro* diagnostic use only. Do not use after expiration date.
3. Do not eat, drink or smoke in the area where the specimens or kits are handled.
4. Do not use test if pouch is damaged.

5. Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout in the collection, handling, storage, and disposal of patient samples and used kit contents.
6. Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are assayed.
7. Viral Transport Media (VTM) may affect the test result; do not store specimens in viral transport media; extracted specimens for PCR tests cannot be used for the test.
8. Wash hands thoroughly after handling.
9. Please ensure that an appropriate amount of samples are used for testing. Too much or too little sample size may lead to deviation of results.
10. The used test should be discarded according to local regulations.
11. Humidity and temperature can adversely affect results.


### **STORAGE AND STABILITY:**

Store as packaged in the sealed pouch at room temperature or refrigerated (2-30°C). The test is stable through the expiration date printed on the sealed pouch. The test must remain in the sealed pouch until use. **DO NOT FREEZE.** Do not use beyond the expiration date.

### **SPECIMEN COLLECTION AND PREPARATION:**

#### **Specimen collection**

1. Insert a sterile swab into the nostril of the patient, reaching the surface of the posterior nasopharynx.
2. Swab over the surface of the posterior nasopharynx.
3. Withdraw the sterile swab from the nasal cavity.



Specimens should be tested as soon as possible after collection. If swabs are not been processed immediately, it is highly recommended the swab sample is placed into a dry, sterile, and tightly sealed plastic tube for storage. The swab specimen in dry and sterile condition is stable for up to 8 hours at room temperature and 24 hours at 2-8°C. Do not store specimens in viral transport media

#### **Specimen preparation**

Only the extraction buffer and tubes provided in the kit is to be used for swab specimen preparation.

1. Place the swab specimen in the Extraction tube with Extraction Buffer (Approx. 350µl). Rotate the swab for approximately 10 seconds while pressing the head against the inside of the tube to release the antigen in the swab.
2. Remove the swab while squeezing the swab head against the inside of the Extraction tube as you remove it to expel as much liquid as possible from the swab. Discard the swab in accordance with your biohazard waste disposal protocol.

\*NOTE: The storage of the specimen after extraction is stable for 2 hours at room temperature or 24 hours at 2-8°C.

### MATERIALS PROVIDED:

- Test cassettes
- Sterile swabs
- Package insert
- Extraction Buffer
- Extraction tubes and tips (Optional)
- Workstation


### MATERIALS REQUIRED BUT NO PROVIDED:

Timer

### TEST PROCEDURE

**Allow the test, extracted specimen and / or controls to equilibrate to room temperature (15-30°C) prior to testing.**

1. Remove the test cassette from the sealed foil pouch and use it within one hour. Best results will be obtained if the test is performed immediately after opening the foil pouch.
2. Invert the specimen extraction tube and add **3 drops of extracted specimen** (approx. 100µl) to the specimen well(S) and then start the timer.
3. Wait for the colored line(s) to appear. Read the result at **15 minutes**. Do not interpret the result after 20 minutes.



**INTERPRETATION OF RESULTS** (please refer to the illustration above):

**POSITIVE COVID-19:**\* **Two distinct colored lines appear in the left window.** One colored line should be in the control region (C) and another colored line should be in the Test region (T). Positive result in the Test region indicates detection of COVID-19 antigens in the sample.

**POSITIVE Influenza A:**\* **Two distinct colored lines appear in the right window.** One colored line should be in the control region (C) and another colored line should be in the Influenza B region (B). Positive result in the Influenza B region indicates that Influenza B antigen was detected in the sample.

**POSITIVE Influenza B:**\* **Two distinct colored lines appear in the right window.** One colored line should be in the control region (C) and another colored line should be in the Test region (T). Positive result in the Test region indicates detection of SARS-CoV-2 antigens in the sample.

**POSITIVE Influenza A and Influenza B:**\* **Three distinct colored lines appear in the right window.** One colored line should be in the control region (C) and two colored lines should be in the Influenza A region (A) and Influenza B region (B). Positive results in the Influenza A and Influenza B regions indicates that Influenza A antigen and Influenza B antigen were detected in the sample.

**\*NOTE:** The intensity of the color in the test line region (T) will vary based on the amount of COVID-19 antigen, Influenza A and / or B antigen present in the sample. So any shade of color in the test region (T / B / A) should be considered positive.

**NEGATIVE:** **One colored line appears in the control region (C).** No apparent colored line appears in the test line region (T / B / A).

**INVALID: Control line fails to appear.** Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test card. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

## **QUALITY CONTROL:**

### **Internal**

Internal procedural controls are included in the test. Colored line appearing in the control region (C) is an internal positive procedural control. It confirms sufficient specimen volume and correct procedural technique. Clear background is an internal negative procedural control. If the test is working properly, the background in the result area should be white to light pink and not interfere with the ability to read the test result.

### **External**

Positive / negative controls are not included in this kit. However, in compliance with Good Laboratory Practice (GLP), these controls are recommended.

## **LIMITATIONS:**

1. The test Procedure and the Interpretation of test Result must be followed closely when testing for the presence of SARS-CoV-2 / Influenza A / Influenza B antigens in the human nasopharyngeal specimens from suspected individuals. For optimal test performance, proper sample collection is critical. Failure to follow the procedure may give inaccurate results.
2. The performance of the Rapid-VIDITEST COVID-19 + Influenza A+B Antigen was evaluated using the procedures provided in this product insert only. Modifications to these procedures may alter the performance of the test. Viral Transport Media (VTM) may affect the test result; extracted specimens for PCR tests cannot be used for the test.
3. The Rapid-VIDITEST COVID-19 + Influenza A+B Antigen is for *in vitro* diagnostic use only. This test should be used for detection of SARS-CoV-2 / Influenza A / Influenza B Antigens in human nasopharyngeal specimens as an aid in the diagnosis of patients with suspected SARS-CoV-2, Influenza A or Influenza B infection in conjunction with clinical presentation and the results of other laboratory tests. Neither the quantitative value nor the rate of increase in the concentration of SARS-CoV-2 / Influenza A / Influenza B antigens can be determined by this qualitative test.

4. The Rapid-VIDITEST COVID-19 + Influenza A+B Antigen will only indicate the presence of SARS-CoV-2 / Influenza A / Influenza B antigens in the specimen and should not be used as the sole criteria for the diagnosis of SARS-CoV-2 / Influenza A / Influenza B infections.
5. The results obtained with the test should be considered with other clinical findings from other laboratory tests and evaluations.
6. If the test result is negative or non-reactive and clinical symptoms persist. It is recommended to re-sample the patient a few days later and test again or test with a molecular diagnostic device to rule out infection in these individuals.
7. The test will show negative results under the following conditions: The concentration of the novel coronavirus antigens, Influenza A or Influenza B virus in the sample is lower than the minimum detection limit of the test.
8. Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.
9. Negative result for Influenza A or Influenza B from this kit should be confirmed by RT-PCR/culture.
10. Excess blood or mucin on the swab specimen may interfere with test performance and may yield a false positive result.
11. The accuracy of the test depends on the quality of the swab sample. False negatives may result from improper sample collection or storage.
12. Positive results of COVID-19 may be due to infection with non-SARS-CoV-2 coronavirus strains or other interference factors. Positive result for Influenza A and / or Influenza B does not preclude an underlying co-infection with another pathogen, therefore the possibility of an underlying bacterial infection should be considered.

#### **EXPECTED VALUES:**

The Rapid-VIDITEST COVID-19 Influenza A+B Antigen has been compared with a leading commercial RT-PCR tests. The correlation between these two system is no less than 97%.

#### **PERFORMANCE:**

##### **Sensitivity, specificity and accuracy**

The Rapid-VIDITEST COVID-19 + Influenza A+B Antigen has been evaluated with specimens obtained from the patients. RT-PCR is used as the reference method for the Rapid-VIDITEST COVID-19 + Influenza A+B Antigen. Specimens were considered positive if RT-PCR indicated a positive result. Specimens were considered negative if RT-PCR indicated a negative result.

#### **COVID-19 test**

Rapid-VIDITEST COVID-19 Antigen		RT-PCR		Total
		Positive	Negative	
COVID-19 Antigen	Positive	80	1	81
	Negative	3	120	123
Total		83	121	204
Relative sensitivity		96,4 %	(95% IS*: 89,8 % ~ 99,2 %)	
Relative specificity		99,2 %	(95% IS*: 95,5 % ~> 99,9 %)	
Accuracy		98,0 %	(95% IS*: 95,1 % ~ 98,5 %)	

## Influenza A+B test

Rapid-VIDITEST COVID-19 + Influenza A+B Antigen		Type A			Type B		
		RT-PCR		Total	RT-PCR		Total
		Positive	Negative		Positive	Negative	
Influenza A+B	Positive	16	1	17	11	0	11
	Negative	1	62	63	1	68	69
Total		17	63	80	12	68	80
Relative sensitivity		94,1 % (95% IS*: 71,3 % ~ 99,9 %)			91,7 % (95% IS*: 61,5 % ~ 99,8 %)		
Relative specificity		98,4 % (95% IS*: 91,5 % ~> 99,9 %)			100,0 % (95% IS*: 95,7 % ~100,0 %)		
Accuracy		97,5 % (95% IS*: 91,3 % ~ 99,7 %)			98,8 % (95% IS*: 93,2 % ~> 99,9 %)		

\* Confidence intervals

### **Specificity testing with various viral strains**

The Rapid-VIDITEST COVID-19 Influenza A+B Antigen was tested with the following viral strains. No discernible line at either of the test-line regions was observed at these concentrations:

#### **COVID-19 test:**

Description	Test Level
Adenovirus type 3	3,16 x 10 <sup>4</sup> TCID50/ml
Adenovirus type 7	1,58 x 10 <sup>5</sup> TCID50/ml
Human coronavirus OC43	2,45 x 10 <sup>6</sup> LD50/ml
Influenza A H1N1	3,16 x 10 <sup>5</sup> TCID50/ml
Influenza A H3N2	1 x 10 <sup>5</sup> TCID50/ml
Influenza B	3,16 x 10 <sup>6</sup> TCID50/ml
Human Rhinovirus 2	2,81 x 10 <sup>4</sup> TCID50/ml
Human Rhinovirus 14	1,58 x 10 <sup>6</sup> TCID50/ml
Human Rhinovirus 16	8,89 x 10 <sup>6</sup> TCID50/ml
Measles	1,58 x 10 <sup>4</sup> TCID50/ml
Mumps	1,58 x 10 <sup>4</sup> TCID50/ml
Parainfluenza virus 2	1,58 x 10 <sup>7</sup> TCID50/ml
Parainfluenza virus 3	1,58 x 10 <sup>8</sup> TCID50/ml
RSV (Respiratory syncytial virus)	8,89 x 10 <sup>4</sup> TCID50/ml

#### **Test Influenza A+B:**

Description	Test Level
Adenovirus type 3	3,16 x 10 <sup>4</sup> TCID50/ml
Adenovirus type 7	1,58 x 10 <sup>5</sup> TCID50/ml
Human coronavirus OC43	2,45 x 10 <sup>6</sup> LD50/ml
Human Rhinovirus 2	2,81 x 10 <sup>4</sup> TCID50/ml
Human Rhinovirus 14	1,58 x 10 <sup>6</sup> TCID50/ml
Human Rhinovirus 16	8,89 x 10 <sup>6</sup> TCID50/ml
Measles	1,58 x 10 <sup>4</sup> TCID50/ml
Mumps	1,58 x 10 <sup>4</sup> TCID50/ml
Parainfluenza virus 2	1,58 x 10 <sup>7</sup> TCID50/ml

Parainfluenza virus 3	1,58 x 10 <sup>8</sup> TCID50/ml
RSV (Respiratory syncytial virus)	8,89 x 10 <sup>4</sup> TCID50/ml

**TCID50** = Tissue Culture Infectious Dose is the dilution of virus that under the conditions of the assay can be expected to infect 50% of the culture vessels inoculated.

**LD50** = Lethal Dose is the dilution of virus that under the conditions of the assay can be expected to kill 50% of the suckling mice inoculated.

## PRECISION:

### Intra-assay and Inter-assay

Within-run and Between-run precision has been determined by using three specimens of COVID-19 and Influenza A / B standard control. Three different lots of the Rapid-VIDITEST COVID-19 + Influenza A+B Antigen have been tested using negative SARS-COV-2 Antigen weak and SARS-COV-2 Antigen Strong, Influenza A Weak, Influenza B Weak, Influenza A Strong and Influenza B Strong. Ten replicates of each level were tested each day for 3 consecutive days. The specimens were correctly identified >99% of the time.

### Cross-reactivity

The following organisms were tested at 1.0x10<sup>8</sup> org/ml and all found to be negative when tested with the Rapid-VIDITEST COVID-19 + Influenza A+B Antigen:

<i>Arcanobacterium</i>	<i>Pseudomonas aeruginosa</i>
<i>Candida albicans</i>	<i>Staphylococcus aureus subspaureus</i>
<i>Corynebacterium</i>	<i>Staphylococcus epidermidis</i>
<i>Escherichia coli</i>	<i>Streptococcus pneumoniae</i>
<i>Moraxella catarrhalis</i>	<i>Streptococcus pyogenes</i>
<i>Neisseria lactamica</i>	<i>Streptococcus salivarius</i>
<i>Nesseria sublava</i>	<i>Streptococcus sp group F</i>

## REFERENCES:

1. Williams, KM, Jackson MA, Hamilton M. (2002) Rapid Diagnostic Testing for URIs in Children; Impact on Physician Decision Making and Cost. *Infect. Med.* 19(3): 109-111.
2. Betts, R.F. 1995. Influenza virus, p. 1546-1567. In G.L. Mandell, R.G. Douglas, Jr. and J.E. Bennett (ed.), *Principle and practice of infectious diseases*, 4th ed. Churchill Livingstone, Inc., New York, N. Y.
3. WHO recommendations on the use of rapid testing for influenza diagnosis, World Health Organisation, July 2005.
4. Westgard JO, Barry PL, Hunt MR, Groth T. A multi-rule Shewhart for quality control in clinical chemistry, *Clinical Chemistry* 1981;27:493-501.

## SYMBOLS FOR IVD COMPONENTS AND REAGENTS

 IVD	For <i>in vitro</i> diagnostics only		Use by
	Store between 2-30 °C		Lot Number
	Do not use if package is damaged		Read instructions
	Manufacturer		Do not reuse
	Tests per kit		Catalog number

Revision date: 29-10-2020